Compare AVY & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVY | CYTK |
|---|---|---|
| Founded | 1935 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | AVY | CYTK |
|---|---|---|
| Price | $181.82 | $61.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 23 |
| Target Price | ★ $199.50 | $109.40 |
| AVG Volume (30 Days) | 535.5K | ★ 1.8M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 0.69 | N/A |
| EPS | ★ 4.85 | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $5.54 | $72.63 |
| Revenue Next Year | $3.17 | $181.06 |
| P/E Ratio | $37.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $152.42 | $57.92 |
| 52 Week High | $199.54 | $88.31 |
| Indicator | AVY | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 37.55 |
| Support Level | $166.02 | $59.21 |
| Resistance Level | $186.84 | $66.63 |
| Average True Range (ATR) | 3.49 | 1.98 |
| MACD | 1.53 | 0.33 |
| Stochastic Oscillator | 81.71 | 31.89 |
Avery Dennison Corp provides materials science and digital identification solutions, offering labeling and functional materials, RFID inlays and tags, software connecting physical and digital, and products that enhance packaging and customer experience. Serving industries including retail, apparel, e-commerce, logistics, food, pharmaceuticals, and automotive it operates through two reportable segments: Materials Group, which manufactures and sells pressure-sensitive label materials, graphics, reflective products, performance tapes, and other adhesive solutions, and earns the majority of revenue; and Solutions Group, which provides brand and price tickets, tags, labels with RFID inlays, and related services, supplies, and equipment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.